“Our data suggest that down-regulation of G9a promotes TPCs, leading to disease progression, metastasis, and worse clinical outcome, thus raising caution for the use of G9a inhibitors, particularly for lung cancer treatment,” the authors concluded. “By studying the epigenetic dependencies of TPC...
In recent years, serious changes have been observed in the treatment algorithms of especially lung cancer patients. The start-up phase of treatment planning of metastatic lung adenocarcinoma patients is comprised of driver mutation research. Among the pretreatment options of patients diagnosed with EML4...
Lung cancer remains the primary cause of cancer-related deaths globally, with lung adenocarcinoma (LUAD) being its most dominant histological subtype1,2. Despite considerable progress in therapeutic approaches for LUAD, particularly with the introduction of immunotherapy, the prognosis remains less than ...
Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all types of lung cancers.1NSCLC is typically diagnosed at advanced stages, resulting in a poor 5-year survival rate of less than 15%.2Intratumoral h...
Four used machine learning and radiology to make a treatment decision or a treatment outcome prediction. This search indicated that, despite an abundance of studies using machine learning with radiology to detect and diagnose lung cancer, there is a scarcity of studies related to its use as a ...
Figure 4. Association of Circulating Tumor (ct)DNA Persistence With Survival View LargeDownload A, Progression-free survival (PFS) in patients with EGFR-mutant lung cancer stratified by clearance of ctDNA after 6 weeks of treatment with osimertinib and bevacizumab. B, Overall survival (OS) in pa...
Lung cancer (LC) is the most frequent type of cancer worldwide and the leading cause of cancer mortality [1]. An essential factor in LC deaths is the invasion and metastasis of cancer cells through the circulation or lymphatic systems, Which is a significant cause of mortality in patients [...
treatment of lung cancer, the prognosis of patients initially harboring sensitive mutations remains unsatisfactory because of acquired drug resistance [4]. Moreover, patients without sensitive mutations could barely benefit from current molecular targeted therapy, and treatment options for them were usually...
Transforming growth factor-β (TGF-β) induces apoptosis in many types of cancer cells and acts as a tumor suppressor. We performed a functional analysis of TGF-β signaling to identify a molecular mechanism that regulated survival in small cell lung cancer cells. Here, we found low expression...
therapeutics. Therefore, we undertake a comprehensive and objective review of literature, aiming to clarify and reconcile contradictory findings in the field and to sort out new directions for cancer treatment. First, we discuss the altered mechano-omics of the primary tumor tissue and cells within ...